Drug
Siremadlin clinical trials
Also written HDM201.
Keep track of what changes. Save the siremadlin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 3 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 4
Novartis Pharmaceuticals (6) · Centre Leon Berard (3) · Insel Gruppe AG, University Hospital Bern (1)
Often tested with
Tested in the same studies.
Trametinib (2) · Ribociclib (2) · Pazopanib (1) · Venetoclax (1) · Azacitidine (1) · Spartalizumab (1) · LCL161 (1) · Everolimus (1)
Studies
Open first, then newest update. How each study uses siremadlin is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Written as HDM201
- HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue SarcomasActive, not recruitingPhase 1/2Centre Leon BerardNCT05180695Written as HDM201
- A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.CompletedPhase 1Novartis PharmaceuticalsNCT05155709Written as siremadlin
- Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic ImpairmentCompletedPhase 1Novartis PharmaceuticalsNCT05599932Written as Siremadlin
- A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell TransplantTerminatedPhase 1/2Novartis PharmaceuticalsNCT05447663Written as Siremadlin
- Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-typeCompletedPhase 1Centre Leon BerardNCT03714958Written as HDM201
- A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedPhase 1Novartis PharmaceuticalsNCT02890069Written as HDM201
- HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.TerminatedPhase 1Insel Gruppe AG, University Hospital BernNCT04496999Written as HDM201
- A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.TerminatedPhase 1Novartis PharmaceuticalsNCT02601378Written as LXS196 and HDM201
- Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With LiposarcomaCompletedPhase 1Novartis PharmaceuticalsNCT02343172Written as HDM201
Given in every arm · 4 — siremadlin is usual care beside what is tested
- HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)TerminatedPhase 1Novartis PharmaceuticalsNCT03940352Written as HDM201
- Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis PatientsTerminatedPhase 1/2Novartis PharmaceuticalsNCT04097821Written as Siremadlin
- Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wtCompletedPhase 1Novartis PharmaceuticalsNCT02143635Written as HDM201
- HDM201 Added to CT in R/R or Newly Diagnosed AMLWithdrawnPhase 1/2Novartis PharmaceuticalsNCT03760445Written as HDM201
Codes
What other systems call siremadlin · ClinicalTrials.gg INT001192
- MeSH (NLM) C000654196siremadlinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0282IF4JC8SIREMADLINConfirmed FDA, NLM
- NCI Thesaurus C116325SiremadlinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654196 | siremadlin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0282IF4JC8 | SIREMADLIN | Confirmed FDA, NLM |
| NCI Thesaurus | C116325 | Siremadlin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.